Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07075185

Phase 1, Recruiting
Active & Responsive

A Study of TAK-505 in Adults With Solid Tumors

for
Malignant Solid Tumors
Location: New York NY, Fairfax VA, Tampa FL, Cleveland OH,
Sponsor: Takeda

Sex: All

Age: 18+

Code: NCT07436728

Phase 1, Phase 2, Recruiting
Active & Responsive

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

for
HER2-positive Early-stage Breast Cancer
Location: Long Branch NJ, Toms River NJ, Elizabeth NJ, Newark NJ,
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18 - 70+

Code: NCT07402473

Phase 2, Recruiting
Active & Responsive

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 18+

Code: NCT07078604

Phase 2, Recruiting
Active & Responsive

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

for
AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma,
Location: New York NY, Orange CA
Sponsor: Rigel Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07486713

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07477886

Recruiting
Active & Responsive

Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening

for
Breast Cancer, Liquid Biopsy, Early Detection
Location: Phoenix AZ
Sponsor: Syantra Inc.

Sex: Female

Age: 30 - 70+

Code: NCT07219277

Recruiting
Active & Responsive

Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients

for
Advanced Cancer
Location: Palo Alto CA
Sponsor: Cancer Commons

Sex: All

Age: 0+

Code: NCT07343024

Recruiting
Active & Responsive

Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers

for
Cancer, Adolescent Cancer, Young Adult Cancer
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 13 - 39

Code: NCT07224204

Recruiting
Active & Responsive

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

for
Advanced Solid Tumors, Metastatic Solid Tumors,
Location: Norwich CT, New York NY, Hackensack NJ, Fairfax VA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT07397338

Phase 1, Phase 2, Recruiting
Active & Responsive

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

for
Solid Tumors (Phase 1), RAS Mutation
Location: Orlando FL, Houston TX
Sponsor: Adlai Nortye Biopharma Co., Ltd.

Sex: All

Age: 18+

Code: NCT07252479

Phase 1, Recruiting
Active & Responsive

iCANSleep: Smartphone App-Based Insomnia Treatment for Cancer Survivors

for
Insomnia, Cancer
Location: St. John's
Sponsor: Memorial University of Newfoundland

Sex: All

Age: 18+

Code: NCT07101302

Recruiting
Active & Responsive

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

for
Solid Tumor
Location: New Haven CT, Charleston SC, Denver CO, Portland OR
Sponsor: Axcynsis Therapeutics Pte Ltd

Sex: All

Age: 18+

Code: NCT06809114

Phase 1, Recruiting
Active & Responsive

IKS014 in Advanced Solid Tumors That Express HER2

for
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Location: Boston MA, Nashville TN, Fort Worth TX,
Sponsor: Iksuda Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT05872295

Phase 1, Recruiting
Active & Responsive

Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors

for
Breast Cancer Survivor, Colorectal Cancer Survivors
Location: Halifax
Sponsor: Nova Scotia Health Authority

Sex: All

Age: 18+

Code: NCT07312786

Recruiting
Active & Responsive

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

for
Malignant Neoplasm
Location: Quebec, New Brunswick NJ, Montreal, Fairfax VA, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07247110

Phase 1, Recruiting
Active & Responsive

Study of PAT in Patients With Solid Tumor Cancers

for
Metastasis, Solid Tumor
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT05338658

Phase 1, Recruiting
Active & Responsive

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT06414278

Recruiting
Active & Responsive

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

for
Advanced Solid Cancers
Location: New York NY, Orlando FL, Detroit MI, Denver CO
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07186842

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: New Haven CT, Philadelphia PA, Fairfax VA,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT07213817

Phase 1, Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial